OverviewSuggest Edit

JanOne (formerly known as ARCA) is a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Its first drug candidate is a treatment for the peripheral arterial disease (PAD), a condition that can cause severe pain.

TypePublic
Founded2019
HQLas Vegas, NV, US
Websitejanone.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2019)208(+36%)
Revenue (FY, 2019)$35.1 M(-4%)
Share Price (Jan 2021)$5.5 (+6%)
Cybersecurity ratingAMore

Key People/Management at JanOne

Tony Isaac

Tony Isaac

CEO & Director
Eric Bolling

Eric Bolling

Director
John Bitar

John Bitar

Director
Richard D. Butler

Richard D. Butler

Director
Virland A. Johnson

Virland A. Johnson

Chief Financial Officer
Nael Hajjar

Nael Hajjar

Director
Show more

JanOne Office Locations

JanOne has an office in Las Vegas
Las Vegas, NV, US (HQ)
325 E Warm Springs Rd
Show all (1)

JanOne Financials and Metrics

JanOne Revenue

JanOne's revenue was reported to be $35.10 m in FY, 2019
USD

Revenue (Q2, 2020)

4.0m

Gross profit (Q2, 2020)

1.0m

Gross profit margin (Q2, 2020), %

26.1%

Net income (Q2, 2020)

(2.4m)

EBIT (Q2, 2020)

(2.3m)

Market capitalization (14-Jan-2021)

10.0m

Closing stock price (14-Jan-2021)

5.5

Cash (27-Jun-2020)

883.0k

EV

16.8m
JanOne's current market capitalization is $10 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

126.7m114.3m129.1m130.9m111.8m103.6m41.5m36.8m35.1m

Revenue growth, %

(15%)(7%)

Cost of goods sold

89.9m86.4m95.2m74.9m28.4m25.7m27.3m

Gross profit

36.7m28.0m33.9m28.7m13.1m11.1m7.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2017Q1, 2017Q2, 2018Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

32.9m35.9m29.4m29.3m29.0m30.4m32.3m33.5m33.5m33.2m33.6m27.5m30.2m27.4m25.3m24.8m23.2m25.8m25.5m8.9m8.4m6.3m7.6m9.8m8.5m4.0m

Cost of goods sold

23.2m25.8m21.8m21.8m22.3m22.5m23.8m24.4m19.2m18.3m17.2m17.1m17.1m6.5m6.2m5.1m5.7m7.2m7.0m3.0m

Gross profit

9.6m10.1m7.6m7.6m6.7m7.9m8.5m9.1m6.2m6.4m6.0m8.7m8.4m2.4m2.2m1.1m1.9m2.6m1.5m1.0m

Gross profit Margin, %

29%28%26%26%23%26%26%27%24%26%26%34%33%27%26%18%25%26%17%26%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.4m3.2m1.9m3.5m3.5m968.0k3.3m1.2m481.0k

Accounts Receivable

7.4m6.3m12.3m10.5m10.0m5.8m6.6m

Prepaid Expenses

1.4m1.3m622.0k761.0k506.0k617.0k356.0k

Inventories

18.5m17.3m16.7m16.3m762.0k801.0k1.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2017Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

4.5m4.7m4.0m3.7m2.8m3.9m2.7m2.1m2.9m2.5m2.9m3.6m3.6m1.7m2.3m2.2m809.0k191.0k2.0m2.1m413.0k652.0k1.4m638.0k837.0k883.0k

Accounts Receivable

9.4m8.2m6.1m6.2m7.3m6.8m9.3m10.8m11.0m6.7m8.8m8.8m12.0m5.9m6.0m4.6m4.9m5.9m4.0m3.3m

Prepaid Expenses

1.2m1.3m1.7m2.5m2.2m1.0m1.3m1.5m1.1m1.1m675.0k2.3m891.0k347.0k1.3m613.0k860.0k854.0k315.0k845.0k

Inventories

16.4m19.0m20.3m21.1m20.5m14.4m14.0m15.2m16.3m15.6m16.3m15.3m15.9m13.2m12.6m11.2m1.2m1.1m975.0k1.0m1.7m1.3m1.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

4.7m(4.5m)3.6m795.0k(3.9m)(1.8m)(378.0k)(5.6m)(12.0m)

Depreciation and Amortization

1.3m1.2m1.4m1.4m1.3m1.3m2.1m4.0m4.1m

Inventories

(1.9m)1.2m620.0k(620.0k)442.0k264.0k(41.0k)(546.0k)

Accounts Payable

(471.0k)491.0k1.6m999.0k59.0k(2.1m)1.7m5.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2017Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

2.7m4.5m(77.0k)(628.0k)(1.8m)129.0k855.0k2.1m1.1m1.7m2.2m(2.0m)(1.5m)(1.7m)(630.0k)(2.8m)1.9m3.9m4.5m(1.5m)(2.9m)(2.0m)(3.4m)(5.4m)(2.3m)(4.7m)

Depreciation and Amortization

667.0k981.0k303.0k609.0k907.0k337.0k680.0k1.0m334.0k676.0k1.0m330.0k648.0k936.0k325.0k634.0k302.0k609.0k1.1m994.0k2.0m1.0m2.0m3.0m1.0m2.0m

Inventories

240.0k(2.4m)(1.8m)(2.7m)(2.1m)2.9m3.2m2.0m447.0k(691.0k)134.0k68.0k544.0k385.0k1.5m801.0k3.1m3.7m5.1m(389.0k)(340.0k)(172.0k)(210.0k)(919.0k)35.0k(481.0k)

Accounts Payable

1.8m3.3m2.4m1.7m1.4m1.3m1.4m3.4m(417.0k)(57.0k)383.0k1.3m1.5m301.0k1.6m744.0k(1.1m)(1.6m)(4.5m)211.0k1.0m520.0k783.0k708.0k(749.0k)(1.5m)
USDQ2, 2012

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

3.1 x
Show all financial metrics

JanOne Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

JanOne Online and Social Media Presence

Embed Graph

JanOne News and Updates

JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

LAS VEGAS, Sept. 24, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has started production of JAN101 under Current...

JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease

LAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has issued its September 2020 Shareholder Letter....

JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials

LAS VEGAS, Sept. 3, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability of its developmental batch run of JAN101. Working closely...

JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness

LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has successfully completed its initial engineering batch of JAN101. The JAN101...

JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications

LAS VEGAS, Aug. 21, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it intends to provide a public business update via...

JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials

LAS VEGAS, Aug. 11, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, together with its manufacturing partner, has successfully completed the...
Show more

JanOne Blogs

Dr. Giordano’s interview with eHealth Radio Network

Our CSO, Dr. Giordano, sat down with @EricDye to discuss JanOne, treating the #opioid industry, bringing to market drugs with non-addictive pain-relieving properties, and more. $JAN #Healthcare #Medical Listen to the full interview here via @eHealthRadio https://ehealthradio.podbean.com/e/janone-treating-the-opioid-industry-and-bringing-to-market-drugs-with-non-addictive-pain-relieving-properties…

Appliance Recycling Centers of America Inc. Announces Major Strategic Shift, Repositioning and Name Change

09-05-2019 – ARCA Announces Major Strategic Shift Repositioning and Name Change

ARCA Recycling Opens New Syracuse, NY Recycling Center

08-26-2019 – ARCA Recycling Opens New Syracuse, NY Recycling Center

JanOne Frequently Asked Questions

  • When was JanOne founded?

    JanOne was founded in 2019.

  • Who are JanOne key executives?

    JanOne's key executives are Tony Isaac, Eric Bolling and John Bitar.

  • How many employees does JanOne have?

    JanOne has 208 employees.

  • What is JanOne revenue?

    Latest JanOne annual revenue is $35.1 m.

  • What is JanOne revenue per employee?

    Latest JanOne revenue per employee is $168.7 k.

  • Who are JanOne competitors?

    Competitors of JanOne include MyoKardia, Reata Pharmaceuticals and PTC Therapeutics.

  • Where is JanOne headquarters?

    JanOne headquarters is located at 325 E Warm Springs Rd, Las Vegas.

  • Where are JanOne offices?

    JanOne has an office in Las Vegas.

  • How many offices does JanOne have?

    JanOne has 1 office.